Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.38 |
| ▸ | MAOA | P21397 | 8/20 | 0.38 |
| ▸ | KDM1A | O60341 | 5/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811682 | 0.79 | MAOB (0.38) | MAOBMAOA | |
| SCHEMBL4345940 | 0.79 | MAOB (0.38) | MAOBMAOAKDM1AOPRM1OPRL1 | |
| SCHEMBL6230490 | 0.76 | MAOA (0.48) | MAOBMAOAKDM1A | |
| SCHEMBL11126717 | 0.75 | LMNA (0.36) | MAOBMAOAKDM1AOPRM1OPRL1 | |
| SCHEMBL8072323 | 0.75 | OPRL1 (0.35) | MAOBMAOAKDM1AOPRM1OPRL1 | |
| SCHEMBL11133978 | 0.73 | HTR2C (0.36) | MAOBMAOAOPRM1 | |
| SCHEMBL4402453 | 0.73 | PTGS2 (0.36) | MAOBMAOAOPRM1 | |
| SCHEMBL8927314 | 0.73 | PTGS2 (0.36) | MAOBMAOAOPRM1 | |
| SCHEMBL13224856 | 0.73 | PTGS2 (0.36) | MAOBMAOAOPRM1 | |
| SCHEMBL28468651 | 0.73 | HTR2C (0.50) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105921-A1 | Process for Preparing Oxazole Intermediates | PHARMACIA & UPJOHN COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-7115747-B2 | Process for preparing oxazole intermediates | PHARMACIA & UPJOHN COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1532123-A1 | PROCESS FOR PREPARING 5-(1, 3-OXAZOL-2-YL) BENZOIC ACID DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040063965-A1 | Process for preparing oxazole intermediates | PHARMACEIA & UPJOHN | 2004-04-01 | — | — | US | disclosed |
| WO-2004000821-A1 | PROCESS FOR PREPARING 5-(1, 3-OXAZOL-2-YL) BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063965-A1 | Process for preparing oxazole intermediates | PSEN1, SOD1, OXA1L | MAOB 168/4885MAOA 72/4885KDM1A 2209/4885 |
| US-20070105921-A1 | Process for Preparing Oxazole Intermediates | OXA1L, SOD1, PSEN1 | MAOB 154/4885MAOA 84/4885KDM1A 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.